FINWIRES · TerminalLIVE
FINWIRES

HKG:2607

5 stories mentioning HKG:2607Updated 4d ago

Every FINWIRES story that references HKG:2607, newest first.

Asia

Shanghai Pharmaceuticals Ends Clinical Trial on Salvianolic Acid A for Injection

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) decided to terminate the clinical trial and development of salvianolic acid A for injection, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's Hong Kong shares rose 2% during Monday's afternoon trade.The drug was intended for the treatment of angina pectoris associated with coronary heart disease.The company said the decision was made to optimize the allocation of funds on projects with "greater strategic advantages".

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Unit Gets China Clinical Trial Approval for Dry Eye Drug

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received clinical trial approval from China's National Medical Products Administration for its Qingrun Yangmu traditional Chinese drug, according to a Tuesday filing with the Shanghai bourse.Qingrun Yangmu, developed by subsidiary Shanghai Pharmaceuticals Group Institute of Traditional Chinese Medicine, is indicated for dry eye.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Arm to Divest 41% Stake in Subsidiary Through Public Listing

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Shanghai Pharmaceutical Holdings will sell a 41% stake in subsidiary Shanghai Pharmaceutical Yiyao Pharmaceutical (Shanghai) for 329.8 million yuan via a public listing, according to a Saturday filing with the Shanghai bourse.Following the transaction, Shanghai Pharma Holdings' ownership in the unit will drop from 51% to 10% and Shanghai Pharmaceutical Holdings will no longer be part of its financial statements.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Gets Nod for Manufacturing of Roxadustat Capsules

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received a drug registration certificate from China's National Medical Products Administration for the manufacturing of Roxadustat capsules, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Hong Kong shares rose 1% during Monday's afternoon trade.The drug is used for the treatment of anemia caused by chronic kidney disease.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.

HKG:2607SHA:601607

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2607 in your portfolio
WheelAI
WheelAI
Analyze HKG:2607 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2607